期刊文献+

补体替代途径中相关因子的激活与年龄相关性黄斑变性的关系 被引量:2

Relationship between some relative factors of the complement alternative pathway and age-related macular degeneration
下载PDF
导出
摘要 年龄相关性黄斑变性(age related macular dengeneration,AMD)是一种与年龄相关的黄斑区退行性病变,最终可导致视力模糊甚至丧失。AMD的发生受到环境和体内炎症反应综合影响,但其具体发病机制至今仍不清楚,目前研究发现由补体替代途径所介导的炎症反应可能起到关键作用。C3(complement component 3)、H因子(complement factor H,CFH)、H因子相关蛋白1和3(complement factor H-related 1 and 3,CFHR1 and CFHR3)、B因子(complement factor B,CFB)、I因子(complement factor I,CFI)在替代途径的激活过程中起到了重要的调节作用。CFH可协同由CFI介导的C3b的裂解过程从而抑制C3转化酶形成,阻滞替代途径的激活。CFHR1和CFHR3作为CFH竞争性因子与CFH争夺C3b上的靶位点并可与CFI协同作用影响补体替代途径的激活。CFB和C3是补体替代途径中的关键因子与AMD中补体替代途径的激活有着密不可分的关系。本文就上述因子的激活在AMD发病过程中的作用进行综述。 Age related macular degeneration ( AMD) is a degenerative disease with the pathological changes in macula lutea and finally leads to the blurred vision even blindness.Environmental and inflammatory reaction may be related with its development.However the exact etiology of the diseases is not clear.AMD is likely a local response of complement alterna-tive pathway which responds to certain systemic inflammatory diseases.Complement component 3 ( C3 ) , complement factor H (CFH), complement factor H-related 1 and 3 (CFHR1 and CFHR3), complement factor B (CFB), and complement factor I ( CFI) are important components in the complement system and also the keys to the pathogenesis of AMD.This re-view is aiming to clarify possible functions of these factors based on recent research.
作者 葛慧敏 李芳
出处 《大连医科大学学报》 CAS 2014年第6期597-600,共4页 Journal of Dalian Medical University
基金 国家自然科学基金项目(30772023)
关键词 年龄相关性黄斑变性 C3 H因子 H因子相关蛋白1和3 B因子 I因子 age related macular degeneration
  • 相关文献

参考文献25

  • 1Amresh Chopdar,Usha Chakravarthy, Dinesh Verma. Age related macular degeneration[J]. BMJ, 2003,326(7387): 485-488.
  • 2Yuzawa M. Study of pathophysiology of age-related macular degeneration[J]. Survey Ophthalmol, 1987,5(31):291-306.
  • 3Thapa R, Paudyal G, Shrestha MK, et al. Age-related macular degeneration in Nepal[J].Kath Univ Med J,2011,9(35):165-169.
  • 4DT Bradley,PF Zipfel, Hughes. Complement in age related macular degeneration:a focus on function[J]. Eye,2011,25(6):683-693.
  • 5Laura A Hecker,Albert O Edwards, Euijung Ryu, et al. Genetic control of the alternative pathway of complement in humans and age related macular degeneration[J]. Hum Mol Genet,2010,19(1):209-215.
  • 6Turiea C. Future methods of treatment in age related macular degeneration[J]. Oftalmologia,2012,56(1):30-35.
  • 7Abedi F, Wickremasinghe S, Richardson AJ, et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration[J]. Ophthalmology, 2013,120(1):115-121.
  • 8Heather Melville, Matthew Carpiniello, Kia Hollis, et al. Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration[J].J Translat Med, 2013, 11(1):53-61.
  • 9Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age related macular degeneration:hypothesis revisited[J]. Prog Retin Eye Res, 2010,29(2):95-112.
  • 10Aldacilene Souza Silva, Anderson Gustavo Teixeira, Lorena Bavia, et al. Plasma levels of complement proteins from the alternative pathway in patients with age related macular degeneration are independent of Complement Factor H Tyr402 His polymorphism[J]. Mol Vis, 2012,18:2288-2299.

同被引文献14

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部